Cytomx Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytomx Therapeutics, Inc. on October 6, 2020. The report discloses a material event regarding the departure of a senior executive and the terms of his retirement and subsequent consulting arrangement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
On October 6, 2020, the Company announced the retirement of Michael Kavanaugh, M.D., SVP, Chief Scientific Officer, Head of Research and Non-Clinical Development, effective December 1, 2020. The departure is accompanied by a Separation Agreement and a new Consulting Agreement.
Guidance, Outlook, and Management Commentary
The filing details the following compensation and transition terms for Dr. Kavanaugh:
- Separation Agreement: Provides economic payments consistent with his Amended and Restated Severance and Change of Control Agreement dated March 25, 2019. It includes a general release of claims against the Company.
- Consulting Arrangement: Effective December 14, 2020, Dr. Kavanaugh will serve as a special advisor for six months at a rate of $250 per hour.
- Scientific Advisory Board: He will serve on the board for an indeterminate period with an annual fee of $15,000.
- Equity Grant: He will receive an option to purchase 12,000 shares of common stock under the 2019 Equity Incentive Plan for his advisory board service.
Full text of the Separation and Consulting Agreements will be filed as exhibits to the Company's Annual Report on Form 10-K for the year ending December 31, 2020.
Investor Verification Checklist
- Verify the specific financial terms of the Separation Agreement in the referenced 2019 Severance and Change of Control Agreement (Exhibit 10.4 to the May 9, 2019 Form 10-Q).
- Review the full text of the Separation and Consulting Agreements when filed as exhibits to the 2020 Form 10-K.
- Confirm the impact of the Chief Scientific Officer's departure on the Company's research and non-clinical development pipeline.
- Assess the total cost of the transition, including the $250/hour consulting rate and the value of the 12,000 share option grant.